Ozempic is a once-weekly injectable medication FDA-approved to treat type 2 diabetes, reduce cardiovascular risk in people with type 2 diabetes and heart disease, and protect kidney function in people with type 2 diabetes and chronic kidney disease. While it’s widely associated with weight loss, Ozempic is not approved for weight management on its own. That’s a separate medication called Wegovy, which contains the same active ingredient at a higher dose.
Type 2 Diabetes: The Primary Use
Ozempic’s core purpose is lowering blood sugar in adults with type 2 diabetes. It works by mimicking a natural hormone called GLP-1 that your body releases after eating. This hormone signals your pancreas to produce more insulin, tells your liver to slow down sugar production, and delays how quickly food leaves your stomach. The result is more stable blood sugar throughout the day.
The blood sugar reductions are significant. In clinical trials, patients taking the 1 mg weekly dose saw their A1C (a measure of average blood sugar over three months) drop by 1.5% to 1.8% after 30 to 56 weeks. Real-world data shows slightly more modest results, with an average A1C reduction of 1.2%, though patients who stayed on the medication consistently saw reductions closer to 1.4%. For context, an A1C drop of 1% or more is considered clinically meaningful and can substantially lower the risk of diabetes complications over time.
Ozempic is typically prescribed alongside diet and exercise changes, and sometimes alongside other diabetes medications. It’s not used for type 1 diabetes.
Cardiovascular Risk Reduction
In January 2020, the FDA expanded Ozempic’s approval to include reducing the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes and established heart disease. This makes it one of the few diabetes medications that does double duty: controlling blood sugar while also protecting the heart.
The approval was based on a two-year trial of over 3,200 patients. Those taking Ozempic had a 26% lower risk of experiencing a major cardiovascular event compared to placebo. Specifically, 6.6% of people in the Ozempic group had a cardiovascular event versus 8.9% in the placebo group. That difference is large enough that many doctors now factor heart disease risk into their decision when choosing a diabetes medication.
Kidney Disease Protection
The newest approved use came in January 2025, when the FDA approved Ozempic for people who have both type 2 diabetes and chronic kidney disease. This approval expanded the medication’s role beyond blood sugar and heart health into kidney protection, offering a way to reduce the risk of serious complications like the need for dialysis or kidney transplant. For the roughly 1 in 3 adults with type 2 diabetes who also have some degree of kidney disease, this added indication is particularly relevant.
Why Ozempic Isn’t the Same as Wegovy
Both Ozempic and Wegovy contain the same drug, semaglutide, but they’re approved for different purposes at different doses. Ozempic tops out at 2 mg per week and is approved for type 2 diabetes and its complications. Wegovy goes up to 2.4 mg per week and is specifically approved for weight management in people with obesity or overweight with at least one weight-related condition.
Ozempic does cause weight loss as a side effect, and this is a major reason it became a household name. But prescribing Ozempic purely for weight loss is considered off-label use. If weight management is your primary goal and you don’t have type 2 diabetes, Wegovy is the version designed for that purpose. Patients switching from Ozempic to Wegovy typically start the transition after being on a stable Ozempic dose for at least four weeks, with the first Wegovy injection given seven days after the last Ozempic dose.
Off-Label Uses Under Investigation
Doctors sometimes prescribe Ozempic for conditions it hasn’t been specifically approved for. The most notable is polycystic ovary syndrome (PCOS), particularly in women with obesity. The American Society for Reproductive Medicine now includes GLP-1 medications like semaglutide as options for managing obesity in women with PCOS, especially those who can’t tolerate metformin. Because PCOS is closely linked to insulin resistance and weight gain, a medication that addresses both can be a practical fit.
Researchers are also exploring semaglutide’s potential in fatty liver disease, neurological conditions, addiction, and autoimmune disorders, though none of these uses have FDA approval.
How the Dosing Works
Ozempic is injected once a week using a prefilled pen, and the dose increases gradually over several months. You start at 0.25 mg weekly for four weeks. This starting dose isn’t really meant to treat your diabetes; it’s designed to let your body adjust and minimize side effects. After four weeks, the dose increases to 0.5 mg. If blood sugar levels still need improvement after another four weeks, the dose can go up to 1 mg, and eventually to the maximum of 2 mg. Each step requires at least four weeks before the next increase.
This slow ramp-up matters because the most common side effects are gastrointestinal, and they tend to be worst during dose increases.
Common Side Effects
Nausea is the side effect most people notice first, followed by vomiting, diarrhea, abdominal pain, and constipation. These affect more than 5% of people taking the medication and are more common at higher doses. In trials comparing the 1 mg and 2 mg doses, gastrointestinal issues occurred in about 31% of people on the lower dose and 34% on the higher one.
For most people, these symptoms are manageable and tend to ease over time. About 3% to 4% of people in clinical trials stopped taking Ozempic because of gastrointestinal side effects, compared to less than 1% on placebo. Severe gastrointestinal reactions were rare, occurring in under 1% of patients.
A few less common concerns worth knowing about: gallstones occurred in up to 1.5% of patients in trials, and people with existing diabetic eye disease saw slightly higher rates of retinopathy complications (3% on Ozempic versus 1.8% on placebo in a two-year cardiovascular trial). If you have diabetic retinopathy, your doctor will likely want to monitor your eyes more closely after starting treatment.